PRTK earnings
Paratek Pharmaceuticals Inc. (PRTK) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ("Paratek" or "the Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corpora
- Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats fo
- Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9About Paratek Phar
- Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek generated total revenue of $160.3 million, primarily as a result of strong growth in NUZYRA® commercial revenue. NUZYRA generated full-year net U.S. sales of $136.8 million in 2022, comprised of $9
- Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call will dial: 877-407-0792 and international investors will dial: 201-689-8263. The conference ID is 13736677. Investors can also access the call at: https://viavid.webcasts.
- Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the Treatment of Pulmonary Anthrax -- Announced Commercial Availability of U.S.-manufactured NUZYRA Tablets BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the quarter ended September 30, 2022. "We are pleased to report another strong quarter of growth in NUZYRA's core commercial business, as evidenced by the 31% increase in net U.S. sales compared to the same per
- Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 800-458-4121 and international investors should dial +1-646-828-8193. The conference ID is 7165992. Investors can also access the event at: https://viavid.webcasts.com/starthere.jsp?ei=1577240&tp_key=22e88571f9.
- Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021 -- Company Reiterates Full Year 2022 Financial Guidance BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the quarter ended June 30, 2022. "The strong year-over-year growth of NUZYRA's core commercial business is a result of accelerating product demand and the disciplined execution of our community sales force expansion, which was initiated in the first quarter of 2021," said Evan Loh, M.D., chief executive officer
- Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the second quarter of 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 877-300-8521 and international investors should dial +1-412-317-6026. The conference ID is 10169245. Investors can also access the event at: https://viavid.webcasts.com/starthere.jsp?ei=1559934&tp_key=28146
- Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022. "Our commercial execution continues to be strong, as demonstrated by the 51% year-over-year first quarter growth from the core NUZYRA commercial business. As the Omicron wave receded, we experienced accelerated product demand thro
- Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial: 877-300-8521 and international investors should dial: +1-412-317-6026. The conference ID is 10166263. Investors can also access the call at https://viavid.webcasts.com/starthere.jsp?ei=1544521&tp_key=032cf0cb
- Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Procurement of NUZYRA under the BARDA Bioshield Contract -- Approval of NUZYRA in China for treatment of ABSSSI and CABP in December 2021; Triggered a $6 Million Milestone Payment from Zai Lab BOSTON, March 14, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021. "We are extremely proud of the 76% year-over-year growth in the core NUZYR
- Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2021. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial: 877-407-0792. International investors should dial: +1 201-689-8263. The conference ID is 13727320. Investors can also access the call at https://viavid.webcasts.com/
- Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior Quarter -- BARDA Contract Expanded to Include sNDA Anthrax Post-Exposure Prophylaxis Development Program; Contract now Valued at up to $304 Million -- First Patient Enrolled in Phase 2b Study in Non-Tuberculous Mycobacterium (NTM) Abscessus BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), today reported financial results and provided an update on corporate activities for the quarter ended September 30, 2021. "We are extremely proud of the 30% quarter-over-quarter growth in the core NUZYRA commercial business despit
- Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30 p.m. EST to provide a corporate update and report its financial results for the third quarter ended Sept. 30, 2021.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304. The conference ID is 10017186. Investors can also access the call at: https://viavid.webcasts.
- Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter -- Reported $37.9 Million in Revenue from the Delivery of the First BARDA Procurement of NUZYRA -- Received FDA Approval of NUZYRA Oral Only Loading-Dose Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) -- Initiated Phase 2b Study in Non-Tuberculous Mycobacterium Abscessus BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening dis
- Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, August 9, 2021 at 4:30 p.m. EDT to provide a corporate update and report its financial results for the second quarter ended June 30, 2021. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPhar